跳至主要内容
临床试验/ACTRN12618001637235
ACTRN12618001637235尚未招募1 期

The effects of a glial inhibitor (palmitoylethanolamide) on brain function and chronic pain intensity in subjects with orofacial neuropathic pain. A pilot study.

niversity of Sydney0 个研究点目标入组 60 人开始时间: 2018年10月3日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Subjects with a diagnosis of orofacial / trigeminal neuropathic pain for longer than 3 months duration
  • Aged over 18 years old
  • Willingness to give written informed consent, willingness to complete a magnetic resonance imaging study, complete various questionnaires and to have a blood sample taken

排除标准

  • Taking daily analgesic medications such as aspirin, ibuprofen, gabapentin, serotonin reuptake inhibitors, anti-depressants for any conditions within 24 hours of study initiation.
  • Claustrophobia
  • Standard MRI exclusion criteria such as the presence of a cardiac pacemaker, artificial heart valve, blood vessel stents, aneurysm clips, cochlear implants, prosthetic devices, magnetically activated implant or device and pregnancy.
  • History of psychological illness or condition such as to interfere with the patient’s ability to understand the requirements of the study.

研究者

相似试验